CME (CME)

Financial Services · Financial Data & Stock Exchanges · S&P 500
$268.96 -0.45% on the day Market cap $98.0B 52-week range $218.31 to $329.16 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
7% a year for 10 years

At a market value of $98.0B, CME's free cash flow of $4.2B (fiscal 2025) would need to grow about 7% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from CME's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price7.0% a year
Free cash flow, last 9 years11.0% a year
Revenue, same period6.8% a year
Price to free cash flow23.4x

Fundamental grade

C

Five factors scored 1 to 9 from CME's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability7
Growth4
Financial health2
Cash efficiency9

Key numbers

P/E (trailing)23.1x
P/E (forward)20.8x
Price / free cash flow23.4x
EV / EBITDA16.8x
Price / sales14.5x
Price / book3.47x
Revenue growth+0.8%
Operating margin65.1%
Net margin63.1%
Return on equity16.1%
Dividend yield1.9%
Debt / equity6.34x

Results from SEC filings

Fiscal years, from CME's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$4.7B$5.0B$5.6B$6.1B$6.5B
Net income$2.6B$2.7B$3.2B$3.5B$4.1B
Free cash flow$2.3B$3.0B$3.4B$3.6B$4.2B
EPS (diluted)$7.29$7.40$8.86$9.67$11.16
Operating margin56.4%60.1%61.6%64.1%64.9%

Where the revenue comes from

Revenue by products, fiscal 2025.

Clearing and Transaction Fees$5.3B81%
MarketData$803M12%
OtherRevenue$436M7%

Superinvestors who own CME

From each investor's latest 13F filing (what a 13F shows). 10 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $448M0.16%Q2 2026
PRIMECAP Management
PRIMECAP Management Co
Added $421M0.25%Q2 2026
Seth Klarman
Baupost Group
New position $137M2.5%Q2 2026
Murray Stahl
Horizon Kinetics LLC
Added $63M0.71%Q2 2026
Hersh Cohen
ClearBridge Investments
Trimmed $51M0.04%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $44M0.10%Q2 2026
Andreas Halvorsen
Viking Global Investors
New position $34M0.10%Q2 2026
Ron Baron
Baron Capital (BAMCO)
Trimmed $11M0.02%Q2 2026
Tom Gayner
Markel Group Inc.
Held $11M0.08%Q2 2026
Mario Gabelli
GAMCO Investors
Trimmed $596,6830.00%Q2 2026

Insider buying

Open-market purchases by CME's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Sep 25, 2026 William R Shepard
Director
293$268.76$78,626
Jan 29, 2026 Ro Khanna
0$289.83—
Jan 29, 2026 Ro Khanna
0$289.83—
Jan 9, 2026 Gilbert Ray Cisneros, Jr.
0$262.45—
Jan 9, 2026 Gilbert Ray Cisneros, Jr.
0$262.45—
Dec 30, 2025 William R Shepard
251$278.37$69,871
Dec 30, 2025 William R Shepard
11$278.37$3,062
Nov 3, 2025 Ro Khanna
0$264.16—
Nov 3, 2025 Ro Khanna
0$264.16—
Oct 7, 2025 Ro Khanna
0$263.60—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when CME trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does CME's stock price imply?

At a market value of $98.0B, CME would need its free cash flow to grow about 7% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 11% a year.

Are CME insiders buying the stock?

10 open-market insider purchases of CME in the last 12 months, from SEC Form 4 filings.

Which superinvestors own CME?

10 of the superinvestors Investingly tracks hold CME in their latest 13F, including Cliff Asness, PRIMECAP Management, Seth Klarman.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.